As for ErbB receptors TKIs, Gefitinib and Erlotinib, which act as reversible inhibitors of EGFR, and Lapatinib, a reversible inhibitor of both EGFR and ErbB2, have also shown a modest activity in HNSCC patients (1, 115). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.